Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
3.100
-0.100 (-3.13%)
Mar 11, 2025, 4:00 PM EST - Market closed
Lipocine Employees
Lipocine had 17 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
17
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$466,054
Profits / Employee
-$238,593
Market Cap
16.58M
Employees Chart
LPCN News
- 4 weeks ago - Lipocine Receives Updated Regulatory Guidance on LPCN 1154 - PRNewsWire
- 3 months ago - FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis - PRNewsWire
- 4 months ago - Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session - PRNewsWire
- 4 months ago - Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 - PRNewsWire
- 4 months ago - Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea - PRNewsWire
- 5 months ago - Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results - PRNewsWire
- 5 months ago - Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries - PRNewsWire
- 5 months ago - Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024 - PRNewsWire